Werewolf Therapeutics (NASDAQ:HOWL) Upgraded at Zacks Research

Zacks Research upgraded shares of Werewolf Therapeutics (NASDAQ:HOWL) from a hold rating to a strong-buy rating in a research report sent to investors on Thursday,Zacks.com reports.

A number of other analysts also recently issued reports on HOWL. Citigroup reaffirmed a “buy” rating on shares of Werewolf Therapeutics in a research note on Monday, August 25th. JMP Securities reduced their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Finally, Bank of America reduced their price objective on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Werewolf Therapeutics Stock Down 4.2%

Shares of HOWL opened at $1.60 on Thursday. The business’s 50 day moving average is $1.56 and its 200 day moving average is $1.25. The company has a market capitalization of $73.17 million, a PE ratio of -0.98 and a beta of 0.76. Werewolf Therapeutics has a 12-month low of $0.60 and a 12-month high of $4.18. The company has a current ratio of 5.30, a quick ratio of 5.30 and a debt-to-equity ratio of 0.60.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.10. Research analysts expect that Werewolf Therapeutics will post -1.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Werewolf Therapeutics

Several large investors have recently modified their holdings of HOWL. Vontobel Holding Ltd. bought a new position in shares of Werewolf Therapeutics during the 1st quarter valued at approximately $34,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Werewolf Therapeutics by 33.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after buying an additional 23,852 shares during the period. Nuveen LLC purchased a new stake in shares of Werewolf Therapeutics in the 1st quarter worth $71,000. MPM Asset Management LLC lifted its holdings in shares of Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after buying an additional 25,688 shares during the period. Finally, MPM Bioimpact LLC lifted its holdings in shares of Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after buying an additional 20,799 shares during the period. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.